First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

Pulmonary hypertension (PH) is associated with impaired production of the vasodilator nitric oxide (NO). Riociguat (BAY 63-2521; Bayer Healthcare AG, Wuppertal, Germany) acts directly on soluble guanylate cyclase, stimulating the enzyme and increasing sensitivity to low NO levels. The present study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European respiratory journal 2009-04, Vol.33 (4), p.785-792
Hauptverfasser:	Grimminger, F, Weimann, G, Frey, R, Voswinckel, R, Thamm, M, Bolkow, D, Weissmann, N, Muck, W, Unger, S, Wensing, G, Schermuly, R. T, Ghofrani, H.A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Analysis of Variance Area Under Curve Biological and medical sciences Chromatography, High Pressure Liquid Female Guanylate Cyclase - biosynthesis Guanylate Cyclase - physiology Hemodynamics - drug effects Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - enzymology Hypertension, Pulmonary - physiopathology Male Medical sciences Middle Aged Nitric Oxide Synthase Type II - pharmacology Oxidation-Reduction Pneumology Pulmonary Circulation - physiology Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases Pyrimidines - pharmacokinetics Pyrimidines - pharmacology Receptors, Cytoplasmic and Nuclear - biosynthesis Receptors, Cytoplasmic and Nuclear - physiology Soluble Guanylyl Cyclase Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!